Among JAK2-first patients, there was an overrepresentation of homozygous PV patients at younger age having a higher risk of thrombotic events, while TET2-first patients were common among both ET and heterozygous PV patients at older age [132]. This evidence concerns the gene JAK2 and essential thrombocythemia.